搜索
 > 【TGF-beta RII】

TGF-beta RII信息

英文名称:Transforming growth factor beta receptor 2
中文名称:转化生长因子β受体2
靶点别称:EC:2.7.11.30,NONHSAG034676,Transforming growth factor-beta receptor type II,TbetaR-II,TGF-beta type II receptor,TGFBR2,Transforming Growth Factor, Beta Receptor II (70/80kDa),Transforming Growth Factor Beta Receptor II,TGFR-2,Transforming Growth Factor, B
上市药物数量:2
临床药物数量:3
最高研发阶段:批准上市

TGF-beta RII产品列表

 
评论(1)
TG2-H52H5|Human TGF-beta RII / TGFBR2 Protein, His Tag
  1. 135XXXXXXX2
  2. 0人赞
  3. 用过很多次acro家的产品,这个蛋白用于细胞功能实验,活性好,实验内表现出非常好的活性和灵敏度。
  4. 2021-10-22
 

TGF-beta RII 分子别名

TGFBR2,TGFR2,TbetaR-II,TGFβR2

TGF-beta RII 分子背景

TGF-beta receptor type-2 (TGFBR2 or TGFR-2) is also known as TGF-beta type II receptor, Transforming growth factor-beta receptor type II, TbetaR-II, TGFβR2, which is a homodimer or heterohexamer, belongs to the protein kinase superfamily, TKL Ser/Thr protein kinase family and TGFB receptor subfamily. TGFR2 / TGFBR2 binds TGF-β1 / TGFB1 and TGF-β3 / TGFB3 with high affinity and TGF-β2 / TGFB2 with a much lower affinity. This type I I receptor forms a heterodimeric complex with type I receptor and is essential for signal transduction. Upon ligand binding, the TGFR2 autophosphorylates its cytoplasmic domain and subsequently phosphorylates the downstream molecules which then enter the nucleus and regulate the transcription of a subset of genes related to cell proliferation.

TGF-beta RII 前沿进展

TGF-beta RII上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Netarsudil Dimesylate AR-13224; AR-13324 批准上市 Aerie Pharmaceuticals Rhopressa EU 高眼压, 开角型青光眼 Aerie Pharmaceuticals Ireland Ltd 2017-12-18 开角型青光眼, 高眼压, 青光眼, 角膜水肿, Fuchs角膜内皮营养不良 详情
Netarsudil mesylate/Latanoprost PG-324 批准上市 Aerie Pharmaceuticals Inc Rocklatan, Roclanda EU 开角型青光眼, 高眼压 Aerie Pharmaceuticals Ireland Ltd 2019-03-12 开角型青光眼, 高眼压 详情

TGF-beta RII临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Adoptive Cell Therapy (Oslo University Hospital) 临床二期 奥斯陆大学医院 结直肠癌 详情
Trabedersen OT-101; OT-201; AP-2/09; AP-12009; AP-2/09-DS 临床三期 Isarna Therapeutics 新型冠状病毒肺炎, 胶质母细胞瘤, 胰腺癌, 结直肠癌, 星形细胞瘤, 黑色素瘤 详情
TASO-001 TASO-001; ATB-301 临床一期 实体瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定